Masimo (NASDAQ:MASI) Price Target Raised to $194.00

Masimo (NASDAQ:MASI) had its target price increased by equities researchers at Raymond James from $170.00 to $194.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical equipment provider’s stock. Raymond James’ price objective indicates a potential upside of 13.44% from the company’s previous close.

Several other research analysts have also weighed in on the stock. Piper Sandler upped their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research increased their price objective on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Wells Fargo & Company lifted their price objective on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $179.67.

Masimo Stock Performance

Shares of MASI stock opened at $171.02 on Friday. The company has a market capitalization of $9.16 billion, a price-to-earnings ratio of 117.94 and a beta of 1.01. Masimo has a 1-year low of $101.61 and a 1-year high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $162.44 and its 200-day simple moving average is $135.91.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.63 EPS. On average, sell-side analysts predict that Masimo will post 4.03 earnings per share for the current fiscal year.

Institutional Trading of Masimo

Institutional investors and hedge funds have recently made changes to their positions in the stock. Edgestream Partners L.P. acquired a new stake in Masimo in the 2nd quarter worth approximately $645,000. Simplify Asset Management Inc. raised its position in shares of Masimo by 120.4% in the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider’s stock valued at $2,729,000 after purchasing an additional 11,838 shares during the period. ING Groep NV lifted its stake in shares of Masimo by 143.3% in the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock worth $32,119,000 after buying an additional 141,900 shares during the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after buying an additional 262,370 shares during the period. Finally, Thrivent Financial for Lutherans grew its stake in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after buying an additional 360,497 shares during the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.